|
🐜
|
Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling
9 auth.
M. Ausems,
J. Verbiest,
M. Hermans,
M. Kroos,
F. Beemer,
J. Wokke,
...
L. Sandkuijl,
A. Reuser,
A. V. D. Ploeg
|
8 |
1999 |
8
🐜
|
|
🐜
|
Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy
11 auth.
C. Gelder,
C. I. Capelle,
B. Ebbink,
I. Moor-van Nugteren,
J. Hout,
M. Hakkesteegt,
...
P. Doorn,
I. Coo,
A. Reuser,
H. D. Gier,
A. Ploeg
|
6 |
2011 |
6
🐜
|
|
🐬
|
Course of disability and respiratory function in untreated late-onset Pompe disease
M. Hagemans,
W. Hop,
P. V. van Doorn,
A. Reuser,
A. T. van der Ploeg
|
6 |
2006 |
6
🐬
|
|
🐢
|
Newborn screening for hunter disease: a small-scale feasibility study.
8 auth.
Gjg Ruijter,
Daphne A Goudriaan,
A. Boer,
J. V. D. Bosch,
A. V. D. Ploeg,
LH. Elvers,
...
SS Weinreich,
A. Reuser
|
4 |
2014 |
4
🐢
|
|
🦁
|
Enzymatic and molecular strategies to diagnose Pompe disease.
7 auth.
A. Reuser,
F. Verheijen,
M. Kroos,
T. Okumiya,
O. V. van Diggelen,
A. T. van der Ploeg,
...
D. Halley
|
3 |
2010 |
3
🦁
|
|
🦁
|
Inconsistent reporting about dosing, dosing regimen, and immunomodulation therapy in Pompe disease
A. Reuser
|
1 |
2012 |
1
🦁
|
|
🐜
|
P4.37 Towards hematopoietic stem cell gene therapy for the treatment of Pompe disease
8 auth.
M. Stok,
H. D. Boer,
T. Visser,
A. Reuser,
E. V. Deel,
D. Duncker,
...
N. V. Til,
G. Wagemaker
|
1 |
2011 |
1
🐜
|
|
🐜
|
M.P.5.01 Two years follow-up of enzyme therapy in five children with Pompe disease
8 auth.
C. Capelle,
N. V. Beek,
M. Hagemans,
W. Arts,
J. Jaeken,
P. Lee,
...
A. Reuser,
A. T. Ploeg
|
0 |
2007 |
0
🐜
|
|
🐜
|
M.P.2.08 Cardiologic evaluation in adults with Pompe disease shows no signs of cardiomyopathy
8 auth.
N. V. Beek,
O. Soliman,
M. Geleijnse,
M. Kroos,
A. Reuser,
W. Vletter,
...
A. T. Ploeg,
P. Doorn
|
0 |
2007 |
0
🐜
|
